References
- Boring C C, Squires T S, Tong T. Cancer statistics, 1992. Cancer 1992; 42: 19–38
- National Center for Health Statistics. Vital Statistics of the United States, 1987, Vol 2, Mortality. U.S. Government Printing Office, Washington, DC 1990
- Ibrahim N K, Buzdar A U. Aromatase inhibitors: Current status. Am J Clin Oncol 1995; 18: 407–417
- Glass A, Hoover R N. Changing incidence of breast cancer. J Natl Cancer Inst 1988; 80: 1076–1077
- Santen R J. Clinical use of aromatase inhibitors in human breast carcinoma. Steroid Biochem Mol Biol 1991; 40: 247–253
- Harris J R, Morrow M, Bonadonna G. Cancer of the breast. Cancer: Principles and Practice of Oncology4th ed., V T DeVita, Jr., S Hellman, S A Rosenberg. JB Lippincott, Philadelphia, PA 1993; 1264–1332
- McGuire W L. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. Hormones and Cancer, S Iacobelli. Raven Press, New York 1980; Vol 15: 337–344
- Bland K I, Fuchs A, Wittliss J L. Menopausal status as a factor in the distribution of estrogen and progestin receptors in breast cancer. Surg Forum 1981; 32: 410–412
- Plourde P V, Dyroff M, Dowsett M, et al. Arimidex®: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995; 53: 175–179
- Yates R A, Dowsett M, Fisher G V, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996; 73: 543–548
- Walton P L, Yates R A, Dukes M. Arimidex: an overview of a new selective nonsteroidal aromatase inhibitor. Sex Hormones and Antihormones in Endocrine Dependent, M Motta, M Serio. Basic Clinical Aspects, Pathology 1994; 311–316
- Package Insert. Arimidex®(anastrozole) tablets. 1995
- Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of an overview analysis of two phase III trials. J Clin Oncol 1996; 14: 2000–2011
- Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404–412
- Plourde P V, Dyroff M, Dukes M. Arimidex®: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30: 103–111
- Goss P E, Gwyn K MEH. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994; 12: 2460–2470
- Brodie A MH. Aromatase, its inhibitors and their use in breast cancer treatment. Pharmacol Ther 1993; 60: 501–515
- Santen R J, Leszcynski D, Tilson-Mallet N, et al. Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulfatase pathways. Ann NY Acad Sci 1986; 464: 126–137
- O'Neill J S, Miller W R. Aromatase activity in breast adipose tissue from women with benign and malignant disease. Br J Cancer 1987; 56: 601–604
- Bradlow H L. A reassessment of the role of breast tumor aromatization. Cancer Res 1982; 42: 3382s–3386s
- Geisler J, Lonning P, Dowsett M, et al. A randomized, double-blind, multicentre, cross-over trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 5 mg p.o. o.d.) in postmenopausal women with breast cancer. Nottingham Breast Cancer Meeting-Zeneca Symposium. NottinghamUK 1995
- Robertson J, Williams M, Todd J. Factors predicting the response of patients with advanced breast cancer endocrine. Eur J Cancer Clin Oncol 1989; 23: 469–475
- Muss H B, Case L D, Capizzi R L, et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 1990; 8: 1797–1805
- Mercer P M, Ebbs S R, Fraser S C, et al. Trial of amino-glutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 1983; 19: 254–258
- Pronzato P, Rubagotti A, Amoroso D, et al. Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation. Am J Clin Oncol 1993; 16: 522–525
- Congdon J, Green S, O'Sullivan J, et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 1991; 10: 43
- Manni A. Pharmacologic manipulation of steroid hormones. Endocrinol Metab Clin North Am 1991; 20: 825–844